Impact of coronavirus disease 2019 on lung cancer patients: A meta-analysis

Wang, Linlin; Wang, Ye; Cheng, Xianbin; Xing-zhao, LI; Li, Jun

doi:10.1016/j.tranon.2022.101605

Cited by 6 publications

(7 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is fair to ask if COVID-19 is a risk factor for complications after VATS lobectomy, given that some patients, after the infection, present alterations in the pulmonary tissue, such as fibrosis and mediastinal lymphadenopathy, that may complicate the surgical dissection. In addition to that, long-term effects of COVID-19 infection, known as Long COVID [ 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 ], include the persistence of respiratory symptoms after COVID-19 infection.…”

Section: Introductionmentioning

confidence: 99%

Outcomes of Thoracoscopic Lobectomy after Recent COVID-19 Infection

et al. 2023

View full text Add to dashboard Cite

Background: The COVID-19 outbreak had a massive impact on lung cancer patients with the rise in the incidence and mortality of lung cancer. Methods: We evaluated whether a recent COVID-19 infection affected the outcome of patients undergoing thoracoscopic lobectomy for lung cancer using a retrospective observational mono-centric study conducted between January 2020 and August 2022. Postoperative complications and 90-day mortality were reported. We compared lung cancer patients with a recent history of COVID-19 infection prior to thoracoscopic lobectomy to those without recent COVID-19 infection. Univariable and multivariable analyses were performed. Results: One hundred and fifty-three consecutive lung cancer patients were enrolled. Of these 30 (19%), had a history of recent COVID-19 infection prior to surgery. COVID-19 was not associated with a higher complication rate or 90-day mortality. Patients with recent COVID-19 infection had more frequent pleural adhesions (p = 0.006). There were no differences between groups regarding postoperative complications, conversion, drain removal time, total drainage output, and length of hospital stay. Conclusions: COVID-19 infection did not affect the outcomes of thoracoscopic lobectomy for lung cancer. The treatment of these patients should not be delayed in case of recent COVID-19 infection and should not differ from that of the general population.

show abstract

Section: Introductionmentioning

confidence: 99%

Outcomes of Thoracoscopic Lobectomy after Recent COVID-19 Infection

et al. 2023

View full text Add to dashboard Cite

show abstract

“…During the first wave of the pandemic in 2020, a Spanish study reported a higher mortality risk from SARS-CoV-2 infection among elderly LC patients compared to the young, and a higher fatality rate of SARS-CoV-2 infection in patients with LC compared to the non-LC population ( 25 ). In addition, a recently published, comprehensive analysis revealed an odds ratio of 4.67 for Covid-19 related mortality among LC patients compared to non-cancer patients, and a 9 times higher risk of death among LC patients with SARS-CoV-2 infection, than non-infected LC patients ( 38 ). However, this analysis did not find higher all-cause mortality in the LC patient population during the Covid-19 pandemic compared to the pre-pandemic era.…”

Section: Discussionmentioning

confidence: 99%

Significant changes in advanced lung cancer survival during the past decade in Hungary: impact of modern immunotherapy and the COVID-19 pandemic

Kiss,

Gálffy,

Müller

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveThe approval of immunotherapy (I-O) for the treatment of late-stage non-small cell lung cancer (NSCLC) opened new perspectives in improving survival outcomes. However, survival data have not yet been provided from the period of the Covid-19 pandemic. The aims of our study were to assess and compare survival outcomes of patients with advanced LC receiving systemic anticancer treatment (SACT) before and after the approval of immunotherapy in Hungary, and to examine the impact of pandemic on survival outcomes using data from the Hungarian National Health Insurance Fund (NHIF) database.MethodsThis retrospective, longitudinal study included patients aged ≥20 years who were diagnosed with advanced stage lung cancer (LC) (ICD-10 C34) between 1 January 2011 and 31 December 2021 and received SACT treatment without LC-related surgery. Survival rates were evaluated by year of diagnosis, sex, age, and LC histology.ResultsIn total, 35,416 patients were newly diagnosed with advanced LC and received SACT during the study period (mean age at diagnosis: 62.1–66.3 years). In patients with non-squamous cell carcinoma, 3-year survival was significantly higher among those diagnosed in 2019 vs. 2011–2012 (28.7% [95% CI: 26.4%–30.9%] vs. 14.45% [95% CI: 13.21%–15.69%], respectively). In patients with squamous cell carcinoma, 3-year survival rates were 22.3% (95% CI: 19.4%–25.2%) and 13.37% (95% CI: 11.8%–15.0%) in 2019 and 2011–2012, respectively, the change was statistically significant. Compared to 2011–2012, the hazard ratio of survival change for non-squamous cell carcinoma patients was 0.91, 0.82, and 0.62 in 2015–2016, 2017–2018, and 2019, respectively (p<0.001 for all cases). In the squamous cell carcinoma group, corresponding hazard ratios were 0.93, 0.87, and 0.78, respectively (p<0.001 for all cases). Survival improvements remained significant in both patient populations during the Covid-19 pandemic (2020–2021). No significant improvements were found in the survival of patients with small cell carcinoma. Platinum-based chemotherapy was the most common first-line treatment in all diagnostic periods, however, the proportion of patients receiving first- or second-line immunotherapy significantly increased during the study period.Conclusion3-year survival rates of NSCLC almost doubled among patients with non-squamous cell carcinoma and significantly improved at squamous cell carcinoma over the past decade in Hungary. Improvements could potentially be attributable by the introduction of immunotherapy and were not offset by the Covid-19 pandemic.

show abstract

“…It has been reported that COVID-19 could increase the risk of lung cancer incidence [ 16 ] and promote lung cancer development [ 29 ]. A meta-analysis study involving more than 300,000 patients found that COVID-19 increases the mortality rate of lung cancer patients [ 30 ]. Research suggests that the SARS-CoV-2 virus, which causes COVID-19, could aggravate lung cancer by inducing chronic inflammation in the lungs [ 31 ].…”

Section: Virus and Lung Cancermentioning

confidence: 99%

Dark under the Lamp: Neglected Biological Pollutants in the Environment Are Closely Linked to Lung Cancer

Wang,

Chan,

Zhang

et al. 2024

IJMS

View full text Add to dashboard Cite

Environmental pollutants are closely linked to lung cancer. The different types of environmental pollutants can be classified as chemical, physical, and biological. The roles of common chemical and physical pollutants such as PM2.5, smoking, radon, asbestos, and formaldehyde in lung cancer have been extensively studied. Notably, the worldwide COVID-19 pandemic raised awareness of the strong link between biological pollution and human health. Allergens such as house dust mites and pollen, as well as bacteria and viruses, are common biological pollutants. A few biological pollutants have been reported to promote lung cancer via inducing inflammatory cytokines secretion, such as IL-1β, IL-6, and TGF-β, as well as suppressing immunosurveillance by upregulating regulatory T (Treg) cells while dampening the function of CD8+ T cells and dendritic cells. However, the correlation between common biological hazards, such as SARS-CoV-2, human immunodeficiency viruses, Helicobacter pylori, and house dust mites, and lung cancer is not fully elucidated, and the underlying mechanisms are still unclear. Moreover, the majority of studies that have been performed in lung cancer and biological carcinogens were not based on the perspective of biological pollutants, which has challenged the systematicity and coherence in the field of biological pollutants in lung cancer. Here, in addition to reviewing the recent progress made in investigating the roles of allergens, viruses, and bacteria in lung cancer, we summarized the potential mechanisms underlying biological pollutants in lung cancer. Our narrative review can shed light on understanding the significance of biological pollutants in lung cancer, as well as inspire and broaden research ideas on lung cancer etiology.

show abstract

Impact of coronavirus disease 2019 on lung cancer patients: A meta-analysis

Cited by 6 publications

References 114 publications

Outcomes of Thoracoscopic Lobectomy after Recent COVID-19 Infection

Outcomes of Thoracoscopic Lobectomy after Recent COVID-19 Infection

Significant changes in advanced lung cancer survival during the past decade in Hungary: impact of modern immunotherapy and the COVID-19 pandemic

Dark under the Lamp: Neglected Biological Pollutants in the Environment Are Closely Linked to Lung Cancer

Contact Info

Product

Resources

About